Fevipiprant reduces airway smooth muscle mass in asthmatics via PGD2 receptor antagonism

Asthma is associated with increased airway smooth muscle (ASM) mass with increased disease severity and impaired lung function. The prostaglandin D2 (PGD2) receptor 2 (DP2) antagonist, fevipiprant, reduces airway eosinophilia and improves epithelial integrity, lung function, ACQ and AQLQ.

Podrobná bibliografie
Hlavní autoři:	Saunders, R, Kaul, H, Berair, R, Singapuri, A, Chernyavsky, I, Chachi, L, Biddle, M, Utcliffe, A, Laurencin, M, Bacher, G, Bourne, M, Pavord, I, Wardlaw, A, Siddiqui, S, Kay, R, Brook, B, Smallwood, R, Brightling, C
Médium:	Conference item
Vydáno:	European Respiratory Society 2017

Fevipiprant reduces airway smooth muscle mass in asthmatics via PGD2 receptor antagonism

Podobné jednotky